Shukra Pharmaceuticals Ltd
NSE: BSE: 524632
₹42.09
(-1.20%)
Thu, 12 Mar 2026, 00:04 pm
Market Cap18.65B
PE Ratio63.21
Dividend0.02
Health Technology
Pharmaceuticals: Major
24.5KShukra Pharmaceuticals Analysis
dividend
- Dividends paid are thoroughly covered by earnings (10.9x coverage).
- Shukra Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Shukra Pharmaceuticals has only been paying a dividend for 3 years, and since then there has been no growth.
- Whilst dividend payments have been stable, Shukra Pharmaceuticals has been paying a dividend for less than 10 years.
- Shukra Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Shukra Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Shukra Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Shukra Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 1.7x debt.
- Shukra Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Shukra Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
- Debt is not well covered by operating cash flow (4%, less than 20% of total debt).
- The level of debt compared to net worth has increased over the past 5 years (1.9% vs 41.1% today).
- Shukra Pharmaceuticals's level of debt (41.1%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Shukra Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
misc
- Shukra Pharmaceuticals is not covered by any analysts.
- Shukra Pharmaceuticals has significant price volatility in the past 3 months.
past
- Shukra Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- Shukra Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Shukra Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Shukra Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Shukra Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Shukra Pharmaceuticals has become profitable in the last year making it difficult to compare the IN Pharmaceuticals industry average.
value
- Shukra Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
- Shukra Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Shukra Pharmaceuticals is good value based on earnings compared to the India market.
- Shukra Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Shukra Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 524632 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524632 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524632 is down -21.2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524632 is down -21.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800